Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 1/2019

06.08.2018 | 2018 SSAT Plenary Presentation

Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival

verfasst von: Heather A. Lillemoe, Yoshikuni Kawaguchi, Guillaume Passot, Georgios Karagkounis, Eve Simoneau, Yi-Qian Nancy You, Reza J. Mehran, Yun Shin Chun, Ching-Wei D. Tzeng, Thomas A. Aloia, Jean-Nicolas Vauthey

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Recurrence rates are high for patients who have undergone two-stage hepatectomy (TSH) for bilateral colorectal liver metastases, and there is no established treatment approach for recurrent disease. This study aimed to determine the feasibility, safety, and prognostic impact of surgical resection for recurrence after TSH and the prognostic role of RAS mutation in this cohort.

Methods

The study included 137 patients intended to undergo TSH for bilateral colorectal metastases during 2003–2016. Clinicopathologic factors were compared using univariate and multivariate analyses.

Results

One hundred eleven patients (81%) completed TSH. The median recurrence-free survival in these patients was 12 months. Of the 83 patients with subsequent recurrence, 31 (37%) underwent resection for recurrence, and 11 underwent multiple resections for recurrence. Forty-eight operations were performed for recurrence: 23 repeat hepatectomies, 14 pulmonary resections, 5 locoregional resections, and 6 concurrent resections in multiple organ sites. The median overall survival (OS) among patients with recurrence was 143 months for patients who underwent resection and 49 months for those who did not (P < 0.001). On multivariate analysis, resection for recurrence (hazard ratio [HR] 0.25; 95% CI 0.10–0.54, P < 0.001) was associated with better OS, whereas RAS mutation (HR 2.25; 95% CI 1.16–4.50, P = 0.016) and first recurrence in multiple sites (HR 2.28; 95% CI 1.17–4.37, P = 0.016) were independent predictors of worse overall survival.

Conclusions

In patients who have undergone TSH for bilateral colorectal liver metastases, recurrence is frequent and should be treated with resection whenever possible. Patients with wild-type RAS fare particularly well with resection for recurrence.
Literatur
1.
2.
Zurück zum Zitat Passot G, Chun YS, Kopetz SE et al. Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. J Am Coll Surg 2016; 223: 99–108.CrossRefPubMedPubMedCentral Passot G, Chun YS, Kopetz SE et al. Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. J Am Coll Surg 2016; 223: 99–108.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Brouquet A, Abdalla EK, Kopetz S et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29: 1083–1090.CrossRefPubMedPubMedCentral Brouquet A, Abdalla EK, Kopetz S et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29: 1083–1090.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Wicherts DA, Miller R, de Haas RJ et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008; 248: 994–1005.CrossRefPubMed Wicherts DA, Miller R, de Haas RJ et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008; 248: 994–1005.CrossRefPubMed
5.
Zurück zum Zitat Narita M, Oussoultzoglou E, Jaeck D et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 2011; 98: 1463–1475.CrossRefPubMed Narita M, Oussoultzoglou E, Jaeck D et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 2011; 98: 1463–1475.CrossRefPubMed
6.
Zurück zum Zitat Lam VW, Laurence JM, Johnston E et al. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013; 15: 483–491.CrossRef Lam VW, Laurence JM, Johnston E et al. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013; 15: 483–491.CrossRef
7.
Zurück zum Zitat Blazer DG, 3rd, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344–5351.CrossRefPubMed Blazer DG, 3rd, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344–5351.CrossRefPubMed
8.
Zurück zum Zitat Passot G, Vauthey JN. In favor of two-stage hepatectomy (TSH). Eur J Surg Oncol 2015; 41: 1566–1567.CrossRefPubMed Passot G, Vauthey JN. In favor of two-stage hepatectomy (TSH). Eur J Surg Oncol 2015; 41: 1566–1567.CrossRefPubMed
9.
Zurück zum Zitat Vakiani E, Janakiraman M, Shen R et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956–2962.CrossRefPubMedPubMedCentral Vakiani E, Janakiraman M, Shen R et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956–2962.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Mullen JT, Ribero D, Reddy SK et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204: 854–862; discussion 862-854.CrossRefPubMed Mullen JT, Ribero D, Reddy SK et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007; 204: 854–862; discussion 862-854.CrossRefPubMed
13.
Zurück zum Zitat Vauthey JN, Zimmitti G, Kopetz SE et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619–626; discussion 626-617.CrossRefPubMed Vauthey JN, Zimmitti G, Kopetz SE et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619–626; discussion 626-617.CrossRefPubMed
14.
Zurück zum Zitat Schirripa M, Bergamo F, Cremolini C et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112: 1921–1928.CrossRefPubMedPubMedCentral Schirripa M, Bergamo F, Cremolini C et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112: 1921–1928.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Margonis GA, Spolverato G, Kim Y et al. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 2015; 22: 4158–4165.CrossRefPubMed Margonis GA, Spolverato G, Kim Y et al. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 2015; 22: 4158–4165.CrossRefPubMed
17.
Zurück zum Zitat Kemeny NE, Chou JF, Capanu M et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 2014; 120: 3965–3971.CrossRefPubMedPubMedCentral Kemeny NE, Chou JF, Capanu M et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 2014; 120: 3965–3971.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kim MJ, Lee HS, Kim JH et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012; 12: 347.CrossRefPubMedPubMedCentral Kim MJ, Lee HS, Kim JH et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012; 12: 347.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Pereira AA, Rego JF, Morris V et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 2015; 112: 424–428.CrossRefPubMed Pereira AA, Rego JF, Morris V et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 2015; 112: 424–428.CrossRefPubMed
20.
Zurück zum Zitat Carlsson U, Lasson A, Ekelund G. Recurrence rates after curative surgery for rectal carcinoma, with special reference to their accuracy. Dis Colon Rectum 1987; 30: 431–434.CrossRefPubMed Carlsson U, Lasson A, Ekelund G. Recurrence rates after curative surgery for rectal carcinoma, with special reference to their accuracy. Dis Colon Rectum 1987; 30: 431–434.CrossRefPubMed
21.
Zurück zum Zitat Yeo HL, Paty PB. Management of recurrent rectal cancer: practical insights in planning and surgical intervention. J Surg Oncol 2014; 109: 47–52.CrossRefPubMed Yeo HL, Paty PB. Management of recurrent rectal cancer: practical insights in planning and surgical intervention. J Surg Oncol 2014; 109: 47–52.CrossRefPubMed
22.
Zurück zum Zitat Adam R, de Gramont A, Figueras J et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015; 41: 729–741.CrossRefPubMed Adam R, de Gramont A, Figueras J et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015; 41: 729–741.CrossRefPubMed
24.
Zurück zum Zitat Colibaseanu DT, Mathis KL, Abdelsattar ZM et al. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? Dis Colon Rectum 2013; 56: 14–19.CrossRefPubMed Colibaseanu DT, Mathis KL, Abdelsattar ZM et al. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? Dis Colon Rectum 2013; 56: 14–19.CrossRefPubMed
Metadaten
Titel
Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival
verfasst von
Heather A. Lillemoe
Yoshikuni Kawaguchi
Guillaume Passot
Georgios Karagkounis
Eve Simoneau
Yi-Qian Nancy You
Reza J. Mehran
Yun Shin Chun
Ching-Wei D. Tzeng
Thomas A. Aloia
Jean-Nicolas Vauthey
Publikationsdatum
06.08.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2019
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-018-3890-y

Weitere Artikel der Ausgabe 1/2019

Journal of Gastrointestinal Surgery 1/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.